|
English
|
正體中文
|
简体中文
|
2826201
|
|
???header.visitor??? :
31834104
???header.onlineuser??? :
1412
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"ngan roger"???jsp.browse.items-by-author.description???
Showing items 1-1 of 1 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2021-10-21T23:28:16Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai, Ming Shen; Feng, Yin Hsun; Chen, Shang Wen; Masuda, Norikazu; Yau, Thomas; Chen, Shou Tung; YEN-SHEN LU; Yap, Yoon Sim; Ang, Peter C.S.; Chu, Sung Chao; Kwong, Ava; Lee, Keun Seok; Ow, Samuel; Kim, Sung Bae; Lin, Johnson; Chung, Hyun Cheol; Ngan, Roger; Kok, Victor C.; Rau, Kun Ming; Sangai, Takafumi; Ng, Ting Ying; Tseng, Ling Ming; Bryce, Richard; Bebchuk, Judith; Chen, Mei Chieh; Hou, Ming Feng |
Showing items 1-1 of 1 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
